Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+/-)Nicotine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 3/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | PSIP1 | O75475 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CHRNG | P07510 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | CHRNA5 | P30532 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+/-)Nicotine SCHEMBL20193 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| R-Nicotine SCHEMBL20518 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL10909351 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL308101 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL4729900 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL10909353 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL1724652 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL2599622 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| (+/-)Nicotine SCHEMBL797620 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 | |
| Nicotine SCHEMBL407606 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CHRNA7CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-03-05 | — | — | US | claimed |
| US-20250338885-A1 | SOFT ORAL PRODUCT | ALTRIA CLIENT SERVICES LLC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4633618-A1 | TREATMENT OF TYPE 2 DIABETES AND/OR CHRONIC KIDNEY DISEASE WITH HEPATOCYTE NUCLEAR FACTOR 4 ALPHA (HNF4A) AGONISTS | Regeneron Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250262248-A1 | METHODS AND COMPOSITIONS FOR TREATING VISION LOSS | CELL CURE NEUROSCIENCES, LTD. (IL) | 2025-08-21 | — | — | US | claimed |
| US-20250241354-A1 | ORAL PRODUCTS | RAI STRATEGIC HOLDINGS INC (US) | 2025-07-31 | — | — | US | claimed |
| EP-4569085-A1 | IN VITRO DERIVATION OF PANCREATIC ISLETS FROM HUMAN PLURIPOTENT STEM CELLS | Spiber Technologies AB (SE) | 2025-06-18 | — | — | EP | claimed |
| EP-4551940-A2 | METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS | Combangio, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119955509-A | Up-down conversion multi-mode luminescent material and preparation method and application thereof | 青岛大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119907853-A | In vitro derivatization of islets from human pluripotent stem cells | 思百博技术股份公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119823036-A | HYNIC modified 4- (2-aminoethyl) benzenesulfonamide derivative and application thereof | 北京师范大学 | 2025-04-15 | — | — | CN | claimed |
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | claimed |
| CN-115279177-A | Genetic method for realizing ultra-low nicotine content in tobacco | 北卡罗来纳州立大学 | 2022-11-01 | — | — | CN | claimed |
| WO-2022225943-A2 | DRUG-REGULATABLE TRANSCRIPTION FACTORS | SENTI BIOSCIENCES, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-20220267474-A1 | METHODS FOR IMPROVING CIRCULATION AND TREATING CARDIOVASCULAR DISEASE | Antidote Therapeutics, Inc. (US) | 2022-08-25 | — | — | US | claimed |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-14 | — | — | US | claimed |
| WO-2022109421-A1 | INDUCIBLE CELL DEATH SYSTEMS | SENTI BIOSCIENCES, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114105951-A | Process for preparing nicotine | 山东金城医药化工有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-11254916-B2 | Methods of making and using PDX1-positive pancreatic endoderm cells | VIACYTE, INC. (US) | 2022-02-22 | — | — | US | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| WO-2015184317-A1 | PHARMACEUTICAL COMPOSITION WITH IONICALLY CROSSLINKED POLYMER ENCAPSULATION OF ACTIVE INGREDIENT | ALLEN ERIC (US) | 2015-12-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | CHRNB2 3/4885CHRNA4 8/4885ALDH1A1 655/4885 |
| US-20250262248-A1 | METHODS AND COMPOSITIONS FOR TREATING VISION LOSS | PDE6C, PDE6D, PDE6H | CHRNB2 24/4885CHRNA4 418/4885ALDH1A1 1378/4885 |
| US-20260060287-A1 | AEROSOLIZABLE COMPOSITION INCLUDING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | CHRM3, CHRM1, ADRA1D | CHRNB2 240/4885CHRNA4 119/4885ALDH1A1 2093/4885 |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | NAPRT, CHRNG, CHRNB2 | CHRNB2 3/4885CHRNA4 8/4885ALDH1A1 655/4885 |
| US-20220267474-A1 | METHODS FOR IMPROVING CIRCULATION AND TREATING CARDIOVASCULAR DISEASE | NNMT, NAPRT, LIPG | CHRNB2 32/4885CHRNA4 78/4885ALDH1A1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.